Form 8-K - Current report:
SEC Accession No. 0001193125-26-012028
Filing Date
2026-01-14
Accepted
2026-01-13 20:07:17
Documents
15
Period of Report
2026-01-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rkda-20260109.htm   iXBRL 8-K 66188
2 EX-4.1 rkda-ex4_1.htm EX-4.1 184675
3 EX-4.4 rkda-ex4_4.htm EX-4.4 178415
4 EX-10.1 rkda-ex10_1.htm EX-10.1 119747
5 EX-99.1 rkda-ex99_1.htm EX-99.1 16893
6 GRAPHIC img192114479_0.jpg GRAPHIC 9353
  Complete submission text file 0001193125-26-012028.txt   769876

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rkda-20260109.xsd EX-101.SCH 24852
17 EXTRACTED XBRL INSTANCE DOCUMENT rkda-20260109_htm.xml XML 4672
Mailing Address 5956 SHERRY LANE SUITE 2000 DALLAS TX
Business Address 5956 SHERRY LANE SUITE 2000 DALLAS TX 214-974-8921
Arcadia Biosciences, Inc. (Filer) CIK: 0001469443 (see all company filings)

EIN.: 810571538 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37383 | Film No.: 26531236
SIC: 1311 Crude Petroleum & Natural Gas
(CF Office: 01 Energy & Transportation)